RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations

Abstract

BackgroundCardiovascular disease remains a major health care challenge. The knowledge about the underlying mechanisms of the respective vascular disease etiologies has greatly expanded over the last decades. This includes the contribution of microRNAs, endogenous non-coding RNA molecules, known to vastly influence gene expression. In addition, short interference RNA has been established as a mechanism to temporarily affect gene expression. This review discusses challenges relating to the design of a RNA interference therapy strategy for the modulation of vascular disease. Despite advances in medical and surgical therapies, atherosclerosis (ATH), aortic aneurysms (AA) are still associated with high morbidity and mortality. In addition, intimal hyperplasia (IH) remains a leading cause of late vein and prosthetic bypass graft failure. Pathomechanisms of all three entities include activation of endothelial cells (EC) and dedifferentiation of vascular smooth muscle cells (VSMC). RNA interference represents a promising technology that may be utilized to silence genes contributing to ATH, AA or IH. Successful RNAi delivery to the vessel wall faces multiple obstacles. These include the challenge of cell specific, targeted delivery of RNAi, anatomical barriers such as basal membrane, elastic laminae in arterial walls, multiple layers of VSMC, as well as adventitial tissues. Another major decision point is the route of delivery and potential methods of transfection. A plethora of transfection reagents and adjuncts have been described with varying efficacies and side effects. Timing and duration of RNAi therapy as well as target gene choice are further relevant aspects that need to be addressed in a temporo-spatial fashion.ConclusionsWhile multiple preclinical studies reported encouraging results of RNAi delivery to the vascular wall, it remains to be seen if a single target can be sufficient to the achieve clinically desirable changes in the injured vascular wall in humans. It might be necessary to achieve simultaneous and/or sequential silencing of multiple, synergistically acting target genes. Some advances in cell specific RNAi delivery have been made, but a reliable vascular cell specific transfection strategy is still missing. Also, off-target effects of RNAi and unwanted effects of transfection agents on gene expression are challenges to be addressed. Close collaborative efforts between clinicians, geneticists, biologists, and chemical and medical engineers will be needed to provide tailored therapeutics for the various types of vascular diseases.

Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium

“…An endothelial focus for preventive and therapeutic interventions against APS moving forward is potentially advantageous because strategies for endothelial cell phenotype manipulation in vivo continue to emerge, such as the use of helper-dependent adenovirus to provide stable transgene expression in the endothelium. 82,83 Nonviral technology using polymeric nanoparticles for endothelial siRNA delivery is also gaining momentum, 84,85 with endothelial-avid nanoparticles enabling multigene silencing already becoming feasible. 86 Now having greater understanding of the molecular underpinnings of the disease, and the cell type in which the processes likely primarily take place, there is hope that the development and application of mechanism-based therapies against APS-related thrombosis has become more feasible.…”

An Emerging Role for Circular RNAs in Osteoarthritis

“…Although this approach is promising, several challenges have been identified in other experiments, including the lack of stability against extracellular and intracellular degradation by nucleases, poor uptake and low potency at target sites of siRNAs, non-specific effects of transfection agents, and off-target effects. 59 60 …”

Ecological aspects of molecular mechanisms of epigenetic rearrangement of humoral systems of the renal function regulation

“…Posttranscriptional expression of genes is regulated by such an epigenetic mechanism as RNA interference. RNA interference is the process of suppressing the activity of genes by the help of microRNA at the stage of transcription, translation, degradation or de-adenylation (Nabzdyk et al, 2017). In this case, the microRNA posses an effect on the intensity with which mRNA is translated into a protein (Dwivedi et al, 2011;Cui et al, 2017).…”